Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPolyrizon Ltd. Ordinary Shares

Polyrizon Ltd. Ordinary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.6498 USD -0.37 ( 3.33%)
Last update at 2026-11-12T15:17:00Z
VOLUME
1436
Market Cap
27.02M

Momentum Score

…

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.65
Low
10.65
High
52 Week Price Range
2.88
Low
18.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Polyrizon Ltd. is a Nasdaq-listed company; publicly available disclosures provide limited detail on its core operations. Long-term growth drivers are not well-documented, though the company may benefit if it clarifies its business model, delivers consistent financial results and executes on stated strategic plans. Investors may find the stock more attractive if future filings improve transparency and demonstrate operational progress.
The principal investment risk is limited public information and potential disclosure or governance gaps that hinder assessment of financial condition and execution risk.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
3.51
ROE
-25.38%
Net Debt
-1.31M
ROCE
-29.77%
Diluted EPS TTM
-5.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.33M -1.54M -0.60M -0.78M -0.71M
Net income -3.33M -1.54M -0.60M -0.78M -0.71M
Selling general administrative 3.65M 0.77M 0.30M 0.53M 0.45M
Selling and marketing expenses - - - 0.01M -
Gross profit -0.34M -0.12M -0.00M -0.01M -0.01M
Reconciled depreciation 0.34M 0.12M 0.00M 0.01M -
Ebit -6.25M -1.54M -0.64M -0.78M -0.71M
Ebitda -5.91M -1.42M -0.63M -0.77M -0.70M
Depreciation and amortization 0.34M 0.12M 0.00M 0.01M 0.01M
Operating income -6.25M -1.30M -0.64M -0.90M -0.70M
Other operating expenses 6.25M 1.30M 0.64M 0.90M 0.70M
Interest expense 3.14M 0.00M 0.00M 0.00M 0.00M
Interest income 0.37M 0.00M 0.00M - -
Net interest income -2.77M -0.03M -0.23M 0.02M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 5.91M 1.30M 0.64M 0.90M 0.70M
Cost of revenue 0.34M 0.12M 0.00M 0.01M 0.01M
Total other income expense net 2.91M -0.24M 0.04M 0.12M -0.01M
Net income from continuing ops -3.33M -1.54M -0.60M -0.78M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.44M 5.55M 0.56M 0.55M 0.69M
Intangible assets 2.55M 2.88M - - -
Other current assets 0.59M 0.10M 0.01M 0.01M 0.02M
Total liab 0.44M 0.26M 0.75M 1.20M 0.69M
Total stockholder equity 20.99M 5.29M 0.06M -0.65M -0.00M
Other current liab 0.44M 0.26M 0.30M 1.20M 0.69M
Common stock - - - - 0.33M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -8.40M -5.07M -3.52M -2.92M -2.14M
Cash 1.31M 2.55M 0.00M 0.04M 0.52M
Total current liabilities 0.44M 0.26M 0.50M 1.20M 0.69M
Net debt -1.31M -2.55M 0.20M -0.04M -0.52M
Short term debt - - 0.20M 0.62M -
Short long term debt - - 0.20M 0.62M -
Short long term debt total - - 0.20M 0.62M -
Other stockholder equity 29.39M 10.35M 3.53M 2.02M 1.56M
Total current assets 12.86M 2.65M 0.05M 0.05M 0.54M
Short term investments 10.97M 0.00M 0.04M 0.00M -
Accumulated other comprehensive income - - -0.20M - -
Non currrent assets other 6.02M - 0.49M 0.48M 0.12M
Non current assets total 8.58M 2.89M 0.51M 0.49M 0.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -16.53M 0.03M 0.00M -0.00M -
Total cashflows from investing activities -16.53M 0.03M - -0.00M -0.02M
Net borrowings 0.00M -0.01M 0.25M 0.65M -
Total cash from financing activities 19.81M 3.67M 0.51M 0.65M 1.02M
Net income -3.33M -1.54M -0.60M -0.78M -0.71M
Change in cash -1.25M 2.55M -0.03M -0.49M 0.51M
Begin period cash flow 2.55M 0.00M 0.04M 0.52M 0.01M
End period cash flow 1.31M 2.55M 0.00M 0.04M 0.52M
Total cash from operating activities -4.53M -1.15M -0.54M -1.13M -0.49M
Issuance of capital stock 19.81M 3.67M 0.26M 0.00M -
Depreciation 0.34M 0.12M 0.00M 0.01M 0.01M
Other cashflows from investing activities -0.53M - - - -
Other cashflows from financing activities - - - -0.65M -
Capital expenditures 0.01M 0.00M 0.00M 0.00M 0.02M
Change in working capital -0.16M -0.02M 0.01M -0.34M 0.03M
Stock based compensation 1.31M 0.05M 0.10M 0.13M 0.18M
Other non cash items -1.38M 0.25M -0.05M -0.14M 0.18M
Free cash flow -4.54M -1.15M -0.54M -1.14M -0.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
PLRZ
Polyrizon Ltd. Ordinary Shares		 -0.37
3.33%		 10.65 - - - 1.24
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Polyrizon Ltd. Ordinary Shares

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

5 HaPnina Street, Ra'anana, Israel, 4321545

972 9 374 0120

https://www.polyrizon-biotech.com

2

Name Title Year Born
Mr. Tomer Izraeli Founder, CEO & Director 1979
Mr. Nir Ben Yosef CFO & Compliance Officer 1976
Dr. Tidhar Turgeman Chief Technology Officer 1977
Dr. Eyal S. Ron Ph.D. Chief Scientific Officer 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…